Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,794 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,294 · Balance 27,794 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2036-06-11 | Direct | 33,540 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 33,540 · Balance 33,540 F3: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 58,371 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 58,371 F2: On July 23, 2025, the Reporting Person transferred 12,491 shares to a living trust for no consideration. The Reporting Person is an indirect beneficial owner of the shares held by the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: On July 23, 2025, the Reporting Person transferred 12,491 shares to a living trust for no consideration. The Reporting Person is an indirect beneficial owner of the shares held by the trust.
F3: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 33,540 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0000882796-26-000053 · form4.xml · derivative · entry 3 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F3 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 15,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000053 · form4.xml · nonDerivative · entry 1 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,794 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 27,181 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001171843-25-003912 · ownership.xml · derivative · entry 3 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F3 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003912 · ownership.xml · nonDerivative · entry 1 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,991 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018711 · form4.xml · derivative · entry 3 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F3 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018711 · form4.xml · nonDerivative · entry 1 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,431 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. F2 · balance_after: The shares purchased by the reporting person on May 13, 2024 were inadvertently reported as being purchased directly by the reporting person but were actually purchased by the reporting person's trust. The reporting person is a trustee of such trust and the reporting person and members of his family are the sole beneficiaries of the trust. The reporting person is an indirect beneficial owner of the shares held by the trust. Read SEC document |
| May 13, 2024 Filed May 15, 2024 11:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 21,940 | $5.49 | $120,450.60 |
DisclosureSEC source: 0001127602-24-015369 · form4.xml · nonDerivative · entry 1 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,551 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.48 to $5.49. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018788 · form4.xml · derivative · entry 2 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018788 · form4.xml · nonDerivative · entry 1 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,611 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017141 · form4.xml · derivative · entry 2 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017141 · form4.xml · nonDerivative · entry 1 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,866 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 20:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantNon-Qualified Stock Option · Derivative | 60,000 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001127602-21-024770 · form4.xml · derivative · entry 1 Galson Steven K · CIK 0001495328 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-09-01 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. F2 · derivative.exercise_date: The option vests 1/36 per month for a period of 36 months, beginning on October 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.